share_log

Avalo Therapeutics | 10-K: FY2023 Annual Report

Avalo Therapeutics | 10-K: FY2023 Annual Report

Avalo Therapeutics | 10-K:2023財年年報
美股SEC公告 ·  03/29 16:08

Moomoo AI 已提取核心訊息

Avalo Therapeutics, a clinical-stage biotechnology company, reported a net loss of $31.5 million for the year ended December 31, 2023, a decrease of $10.1 million from the previous year. This reduction was primarily due to a $26.2 million decrease in operating expenses, offset by a $14.2 million decrease in license and other revenue. The company's research and development expenses decreased by $17.5 million, attributed to fewer development programs and the completion of the AVTX-002 PEAK Trial. Selling, general and administrative expenses also saw a reduction of $10.4 million due to lower infrastructure costs and headcount. Avalo ended the year with $7.4 million in cash and cash equivalents after raising approximately $46.2 million from equity financings and retiring $35 million of debt. The company's lead asset, AVTX-009, an anti...Show More
Avalo Therapeutics, a clinical-stage biotechnology company, reported a net loss of $31.5 million for the year ended December 31, 2023, a decrease of $10.1 million from the previous year. This reduction was primarily due to a $26.2 million decrease in operating expenses, offset by a $14.2 million decrease in license and other revenue. The company's research and development expenses decreased by $17.5 million, attributed to fewer development programs and the completion of the AVTX-002 PEAK Trial. Selling, general and administrative expenses also saw a reduction of $10.4 million due to lower infrastructure costs and headcount. Avalo ended the year with $7.4 million in cash and cash equivalents after raising approximately $46.2 million from equity financings and retiring $35 million of debt. The company's lead asset, AVTX-009, an anti-IL-1β monoclonal antibody, is expected to enter Phase 2 trials for the treatment of hidradenitis suppurativa (HS) with topline data anticipated in 2026. Avalo acquired the asset through the purchase of AlmataBio in March 2024 and secured $185 million in private placement financing, estimating net proceeds of approximately $105 million. The company's strategy focuses on progressing its immunology drug candidates towards commercialization or out-licensing, with an increase in research and development expenses expected in 2024.
臨床生物技術公司Avalo Therapeutics報告稱,截至2023年12月31日,淨虧損3150萬美元,比去年減少1010萬美元。這一降幅主要是由於營業費用減少了2620萬美元,而許可和其他收入減少了1420萬美元所致。該公司的研發費用減少了1750萬美元,這歸因於開發項目減少和AVTX-002 PEAk試驗的完成。由於製造行業成本和人員數量減少,銷售、一般和管理費用也同樣減少了1040萬美元。Avalo在股權融資中籌集了約4620萬美元並償還了3500萬美元債務後,年底現金及現金等價物餘額爲740萬美元。該公司的主力資產AVTX-009是一種抗IL-1β單克隆抗體,預計將進入II期用於...展開全部
臨床生物技術公司Avalo Therapeutics報告稱,截至2023年12月31日,淨虧損3150萬美元,比去年減少1010萬美元。這一降幅主要是由於營業費用減少了2620萬美元,而許可和其他收入減少了1420萬美元所致。該公司的研發費用減少了1750萬美元,這歸因於開發項目減少和AVTX-002 PEAk試驗的完成。由於製造行業成本和人員數量減少,銷售、一般和管理費用也同樣減少了1040萬美元。Avalo在股權融資中籌集了約4620萬美元並償還了3500萬美元債務後,年底現金及現金等價物餘額爲740萬美元。該公司的主力資產AVTX-009是一種抗IL-1β單克隆抗體,預計將進入II期用於治療汗腺炎(HS),並預計在2026年公佈主要成果數據。Avalo於2024年3月通過購買AlmataBio獲得了這一資產,並獲得了18500萬美元的定向增發融資,估計淨收益約爲10500萬美元。該公司的策略是將免疫藥物候選品推向商業化或轉讓,預計2024年研發費用增加。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息